Last mentioned: Feb 26, 2026
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
This page surfaces every story mentioning Intellia Therapeutics across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Intellia Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |